About BCL2
The BCL2 gene (BCL2 Apoptosis Regulator) on chromosome 18q21 The t(14;18) translocation placing BCL2 under the immunoglobulin heavy chain enhancer drives follicular lymphoma pathogenesis. Key targets include Exons 1–301–3 for comprehensive mutation screening.
Mutations: t(14;18) translocation, amplification | GC content: 58% | Target exons: Exons 1–301–3
BCL2 Primer Design Challenges
- t(14;18) breakpoint diversity: Major breakpoint region (MBR) and minor cluster region (mcr) require translocation-specific primer pairs
- High GC content (58%): The 5' regulatory CpG island influences promoter accessibility and primer binding
- Alternative splicing: Three splice variants (BCL2α, β, γ) complicate isoform-specific detection
Recommended Primer Design Parameters for BCL2
| Parameter | Standard Exons | GC-Rich Regions (≥58%) |
|---|---|---|
| Primer length | 20–22 nt | 22–25 nt |
| GC content | 45–55% | 50–60% |
| Tm | 58–62°C | 60–65°C |
| Amplicon size | 150–300 bp | 180–350 bp |
| Annealing temp | 58–60°C | 60–64°C (touchdown) |
| PCR additive | Standard | Add 5–10% DMSO or betaine |
Recommended Primer Sequences for BCL2
| Target Region | Forward Primer (5′→3′) | Reverse Primer (5′→3′) | Amplicon |
|---|---|---|---|
| Exon 2 (BH4 domain) | 5′-CAGCTGTGGAGATGGTGATG-3′ | 5′-AACTGAGCAGTGCCTTCAGA-3′ | 165 bp |
| Exon 3 (BH1 domain) | 5′-TGATGGGATCGTTGCCTTAT-3′ | 5′-CACAAAGGCATCCCAGCCTC-3′ | 189 bp |
Key SNPs to Avoid in Primer Binding Sites
When designing BCL2 primers, avoid these clinically significant variants:
- rs1801018 (A21T) — Exon 1 synonymous variant
- rs4987855 (F104F) — Exon 2 polymorphism
Clinical Validation Required
All BCL2 primers designed with VigyanLLM are for research use only. Clinical diagnostic applications require additional wet-lab validation, Sanger sequencing confirmation, and regulatory approval before patient use.
Design BCL2 Primers Now
Pre-configured with BCL2-specific parameters. Use our primer design, Tm calculator, and GC content tools for optimal results.